Covid-19: EU panel ‘convinced’ AstraZeneca benefit outweighs risk factor

The European Medicines Agency urged governments not to halt use of the vaccine at a time when the pandemic is still taking thousands of lives each day.

The European Union’s drug regulator insisted on Tuesday that there is “no indication” the AstraZeneca vaccine causes blood clots as governments around the world faced the grimmest of dilemmas: push on with a vaccine known to save lives or suspend its use over reports of clotting in some recipients.

The European Medicines Agency urged governments not to halt use of the vaccine at a time when the pandemic is still taking thousands of lives each day. And already there are concerns that even brief suspensions could have disastrous effects on confidence in inoculation campaigns the world over, many of which are already struggling to overcome logistical hurdles and widespread hesitancy about experimental vaccines.

“We are still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19 with its associated risk of hospitalisation and death outweigh the risk of the side effects,” said Emer Cooke, the head of the agency.